Abstract P5-11-11: A Phase I Safety Study of Topical Calcitriol (BPM31543) for the Prevention of Chemotherapy-Induced Alopecia

February 2017 in “ Cancer Research ”

SB Goldfarb, J. Konner, J Stevens, S. Brouwer, NR Narain, R. Ye, S Ravipaty, R Sarangarajan, VR Akmaev, JJ Jimenez, VR Belum, S. Kitts, K Ciccolini, B. Berman, ME Lacouture

calcitriol BPM31543 chemotherapy-induced alopecia CIA taxane-based chemotherapy

Studysummary In this study involving women undergoing taxane-based chemotherapy, a twice-daily topical application of BPM31543 was well-tolerated and showed potential in reducing severe hair loss, prompting further investigation at higher doses.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer ·

View this study on aacrjournals.org →

Discuss this study in the Community →

Similar Research

5 / 1000+ results

research A phase I safety study of topical calcitriol (BPM 31543) for the prevention of chemotherapy-induced alopecia (CIA).

1 citations , May 2017 in “Journal of Clinical Oncology”

This study found that applying BPM 31543 twice daily was safe, well-tolerated, and showed signs of reducing chemotherapy-induced alopecia in women receiving taxane-based chemotherapy.

research Safety, tolerability, and PK of topical calcitriol formulation for treatment of chemotherapy-induced alopecia (CIA) in patients receiving taxane-based regimen: Final results.

May 2019 in “Journal of clinical oncology”

This Phase 1 study reported that topical application of BPM31543 was safe and well-tolerated in patients receiving taxane-based chemotherapy, with some experiencing less than 50% hair loss, suggesting potential efficacy in reducing chemotherapy-induced alopecia, although no maximum tolerated dose was identified.

A Phase I Safety Study of Topical Calcitriol (BPM31543) for the Prevention of Chemotherapy-Induced Alopecia: Final Study Results

research A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia (CIA): Final study results

October 2018 in “Annals of oncology”

This study reported that topical BPM31543 was safe and well-tolerated for patients on taxane-based chemotherapy, with some efficacy indicated in reducing hair loss at all dosages tested.

research Topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia (CIA): Efficacy findings from a phase I safety study.

2 citations , May 2016 in “Journal of Clinical Oncology”

This study found that topical BPM31543 was safe, tolerable, and showed potential to reduce chemotherapy-induced alopecia at higher dosing levels among adult women with cancer receiving taxane-based chemotherapy.

research Reduction of Intrafollicular Apoptosis in Chemotherapy-Induced Alopecia by Topical Calcitriol-Analogs

53 citations , October 1998 in “The journal of investigative dermatology/Journal of investigative dermatology”

This study found that cyclophosphamide induced significant keratinocyte apoptosis in anagen hair follicles of mice, while topical calcitriol-analogs reduced this apoptosis, suggesting a protective effect against chemotherapy-induced alopecia.